Predicting Treatment Response in Early Triple-Negative Breast Cancer
Part of Cancer, Skin clinical trials.
This study helps doctors predict which patients will respond best to immunochemotherapy (a combination of immune-boosting and chemotherapy drugs) for early-stage triple-negative breast cancer. By understanding your tumor better before treatment, doctors may be able to personalize your care plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female, age 18 or older
- Diagnosed with triple-negative breast cancer (a type where three common growth signals are absent), stage II or III
- Eligible to receive the immunochemotherapy combination used in the Keynote-522 trial
- Willing to have a small marker clip placed inside the tumor during a biopsy
- Not pregnant or breastfeeding
- No known bleeding or clotting disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy and immunotherapy given before surgery for early-stage triple-negative breast cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a less intense chemotherapy regimen (without one of the standard drugs) combined with immunotherapy for people with early-stage triple-negative breast cancer whose tumors have a high level of immune cells (TILs). The goal is to see if this approach is effective while reducing side effects.
This trial tests whether people with early stage triple-negative breast cancer and a high level of immune cells in the tumor can safely skip chemotherapy after surgery. It aims to find a less intensive treatment option for those who may not need strong drugs.
This study collects small tissue samples from your breast cancer before, during, and after chemotherapy and immunotherapy to identify early signs of how well the treatment is working. The goal is to better predict treatment response and improve outcomes for patients with triple-negative or high-risk hormone-positive breast cancer.
This trial tests whether using blood tests and MRI imaging to monitor how your tumor responds can help doctors personalize your chemotherapy and immunotherapy treatment before surgery. The goal is to improve outcomes for people with early-stage triple-negative breast cancer.
This study looks for “biomarkers,” or tumor clues, that may help predict who benefits from checkpoint inhibitor immunotherapy in triple-negative breast cancer. It may help doctors choose the right treatment approach in the future, especially when chemotherapy is planned.
Hear when a new Triple-negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.